Gender differences in psychotropic medications

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 326-329

  Lewis Hall, Freda ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; DIAZEPAM; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NITRAZEPAM; NORTRIPTYLINE; OXAZEPAM; PHENELZINE; PSYCHOTROPIC AGENT; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT;

HUMAN; PSYCHOPHARMACOTHERAPY; REVIEW; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; EPIDEMIOLOGIC FACTORS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 0029851056     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Chouinard G, Annable I. Pimozide in the treatment of newly schizophrenic patients. Psychopharmacology (Berl) 1982; 76:13-19.
2. Fields IZ, Gordon JH. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sci 1982; 30:229-234.
3. Villeneuve A, Langlier P, Bedard P. Estrogens, dopamine and dyskinesias. Can Psychiatr Assoc J 1978; 23:68-70.
4. Chouinard G, Annable I, Steinberg S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1986; 6:21-26.
5. Seeman MV. Interaction of sex, age and neuroleptic dose. Compr Psychiatry 1983; 24:125-128.
6. DiMello DA, MacNeil JA. Sex differences in bipolar affective disorder; neuroleptic dosage variance. Compr Psychiatry 1990; 31:80-83.
7. Simpson GM, Yakalam KG, Levinson DP, et al. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol 1990; 10:417-421.
8. Ereshetsky L, Saklad SR, Watanabe MD, et al. Thiothixene-pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11: 269-301.
9. Smith JM, Dunn DD. Sex differences in the prevalence of severe tardive dyskinesia. Am J Psychiatry 1979; 136: 1080-1082.
10. Chouinard G, Annable I, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry 1979; 136:79-83.
11. Smith JM, Kucharski IT, Oswald WT. Tardive dyskinesia: effect of age, sex, and criterion level of symptomatology on prevalence estimates. Psychopharmacol Bull 1979; 5:69-71.
12. Chouinard G, Jones BD, Annable I, Ross-Chouinard A. Sex differences and tardive dyskinesia (letter). Am J Psychiatry 1980; 137:507.
13. Yassar, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Psychol Bull 1992; 1814:701-715.
14. Jeste DV. Gender and ethnicity differences in pharmacology of neuroleptics. American Psychiatric Association Annual Meeting 1995.
15. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54:466-469.
16. Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977; 34:98-111.
17. Davidson J, Pelton S. Forms of atpyical depression and their response to antidepressant drugs. Psychiatr Res 1986; 17:87-95.
18. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974; 159:120-130.
19. Burrows G, Scoggins BA, Turecek IR, Davies B. Plasma nortriptyline and clinical response. Clin Pharmacol Ther 1974; 16:639-644.
20. Zeigler VI, Biggs JT. Tricyclic plasma levels: effect of age, race, sex and smoking. J Am Med Assoc 1977; 238: 2167-2169.
21. Preskorn SH, Mac DS. Plasma level of amitriptyline: effect of age and sex. J Clin Psychiatry 1985; 46:276-277.
22. Moody JP, Tait AC, Todrick A. Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry 1967; 113:183-193.
23. Greenblatt DJ, Friedman H, Bernstein ES, et al. Trazodone kinetics: effect of age, gender and obesity. Clin Pharmacol Ther 1987; 42:193-200.
24. Abernathy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984; 35:792-797.
25. Conrad CD, Hamilton JA. Recurrent premenstrual decline in serum lithium concentration. J Am Acad Child Psychiatry 1986; 26:852-853.
26. Kukopulos A, Minnai G, Muller-Oelinghausen B. The influence of mania and depression on the pharmacokinetics of lithium: a longitudinal single-case study. J Affect Disord 1985; 8:159-166.
27. Chamberlain S, Hahn PM, Cassan P, Reid RL. Effect of menstrual cycle phase and oral contraceptive use on serum lithium levels after a loading dose of lithium in normal women. Am J Psychiatry 1990; 147:907-909.
28. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27:301-312.
29. Macleod SM, Giles HG, Bengerr B, et al. Age and gender related differences in diazepam pharmacokinetics. J Clin Pharmacol 1979; 19:15-19.
30. Smith RB, Divoll M, Gillespíe WR, Greenblatt DJ. Effect of subject age and gender on the pharmacokinetics of oral triazolam and remazepam. J Clin Psychopharmacol 1983; 3:172-176.
31. Jochemsen R, Van der Graaff M, Boeijinga JK, Breimel D. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 1982; 13:319-324.
32. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. J Pharm Sci 1981; 70:1104-1107.
33. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980; 215:86-91.
34. Giles HG, Sellers EM, Naranjo CA, Greenblatt DJ. Disposition of intravenous diazepam in young men and women. Eur J Clin Pharmacol 1981; 20:207-213.
35. Ellinwood EH, Easier MP, Linnoila M, et al. Effects of oral contraceptives and diazepam-induced psychomotor impairment. Clin Pharmacol Ther 1983; 35:360-366.
36. Dawkins K, Potter WZ. Gender differences pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull 1991; 27:417-426.